News
ABBV
250.82
+0.83%
2.06
AbbVie Price Target Announced at $300.00/Share by Wolfe Research
Dow Jones · 7h ago
AbbVie Raised to Outperform From Peer Perform by Wolfe Research
Dow Jones · 7h ago
Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target
Benzinga · 7h ago
Pharma companies sour on Swiss drug applications amid Trump’s MFN policy
Seeking Alpha · 8h ago
Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA), AbbVie (ABBV) and Establishment Labs Holdings (ESTA)
TipRanks · 8h ago
American Century Focused Global Growth Fund Q2 2026 Portfolio Review
Seeking Alpha · 15h ago
Did AbbVie’s Strong Q2, Higher 2026 Guidance, and New Approvals Just Shift AbbVie’s (ABBV) Investment Narrative?
Simply Wall St · 1d ago
AbbVie’s BOTOX Jawline Trial Wraps Up: What the Masseter Study Means for ABBV Investors
TipRanks · 1d ago
AbbVie’s Venetoclax Combo in High-Risk MDS: What a Fresh Trial Update Signals for Investors
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), AbbVie (ABBV) and Legend Biotech (LEGN)
TipRanks · 1d ago
AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool · 2d ago
What Is AbbVie (ABBV) Poised To Gain From FDA Review Of New BOTOX Use?
Simply Wall St · 2d ago
AbbVie Price Target Raised to $247.00/Share From $218.00 by BNP Paribas
Dow Jones · 2d ago
AbbVie Is Maintained at Neutral by BNP Paribas
Dow Jones · 2d ago
BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247
Benzinga · 2d ago
Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?
The Motley Fool · 2d ago
AbbVie Targets Key Lung Cancer Market With New Phase 3 ABBV-1480 Trial
TipRanks · 2d ago
Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
PR Newswire · 2d ago
AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?
The Motley Fool · 2d ago
Healthcare Investing Is Now an AI Short in Disguise
The Wall Street Journal · 2d ago
More
Webull provides a variety of real-time ABBV stock news. You can receive the latest news about Abbvie Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.